These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32592841)

  • 1. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.
    Esam Z
    Diabetes Res Clin Pract; 2020 Sep; 167():108282. PubMed ID: 32592841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?].
    Pan Y; Han R; He Y
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Sep; 32(9):1131-1134. PubMed ID: 33081905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
    Parra-Lara LG; Martínez-Arboleda JJ; Rosso F
    J Glob Antimicrob Resist; 2020 Sep; 22():680-684. PubMed ID: 32622008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 Drug Discovery Using Intensive Approaches.
    Asai A; Konno M; Ozaki M; Otsuka C; Vecchione A; Arai T; Kitagawa T; Ofusa K; Yabumoto M; Hirotsu T; Taniguchi M; Eguchi H; Doki Y; Ishii H
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19.
    Ortiz-Martínez Y
    Travel Med Infect Dis; 2020; 37():101678. PubMed ID: 32325121
    [No Abstract]   [Full Text] [Related]  

  • 8. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).
    Abedi F; Rezaee R; Karimi G
    Pharmacol Res; 2020 Jun; 156():104808. PubMed ID: 32283223
    [No Abstract]   [Full Text] [Related]  

  • 9. Teicoplanin: an alternative drug for the treatment of COVID-19?
    Baron SA; Devaux C; Colson P; Raoult D; Rolain JM
    Int J Antimicrob Agents; 2020 Apr; 55(4):105944. PubMed ID: 32179150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Structure of SARS-CoV-2 and treatment of COVID-19].
    Chen HX; Chen ZH; Shen HH
    Sheng Li Xue Bao; 2020 Oct; 72(5):617-630. PubMed ID: 33106832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential effects of curcumin in the treatment of COVID-19 infection.
    Zahedipour F; Hosseini SA; Sathyapalan T; Majeed M; Jamialahmadi T; Al-Rasadi K; Banach M; Sahebkar A
    Phytother Res; 2020 Nov; 34(11):2911-2920. PubMed ID: 32430996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
    Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
    EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good.
    Gray PE; Belessis Y
    Pharmacol Res; 2020 Jun; 156():104776. PubMed ID: 32251726
    [No Abstract]   [Full Text] [Related]  

  • 15. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    Xu J; Shi PY; Li H; Zhou J
    ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
    Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
    Front Immunol; 2020; 11():1949. PubMed ID: 32849654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective.
    Hammarström L; Abolhassani H; Baldanti F; Marcotte H; Pan-Hammarström Q
    J Allergy Clin Immunol; 2020 Jul; 146(1):58-60. PubMed ID: 32413374
    [No Abstract]   [Full Text] [Related]  

  • 18. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
    O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
    Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.
    Meng X; Ling Y; Zhang L; Zhang Q; Dong P; Zhu T; Lu H
    Biosci Trends; 2020 Jul; 14(3):161-167. PubMed ID: 32536632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic effects of Resveratrol against SARS-CoV-2.
    Ramdani LH; Bachari K
    Acta Virol; 2020; 64(3):276-280. PubMed ID: 32985211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.